null
SMILES: OC(=O)c1nnc(Cc2cc(cn3cc(Cn4cc(nn4)C(=O)NCc4cn5c(F)c(Cl)ccc5n4)nc23)C2CC2)o1
InChI Key: InChIKey=BMCVXVOXDQSAET-UHFFFAOYSA-N
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasma kallikrein (Homo sapiens (Human)) | BDBM455192 (US10730874, Compound I-210a) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <1 | n/a | n/a | n/a | n/a |
Shire Human Genetic Therapies, Inc. US Patent | Assay Description Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s... | US Patent US10730874 (2020) BindingDB Entry DOI: 10.7270/Q2RN3BXC | |||||||||||
More data for this Ligand-Target Pair |